- Home
- ATRA vs PEPG Comparison
ATRA vs PEPG Comparison
Compare ATRA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- PEPG
- Stock Information
- Founded
- ATRA 2012
- PEPG 2018
- Country
- ATRA United States
- PEPG United States
- Employees
- ATRA N/A
- PEPG N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- PEPG Health Care
- Exchange
- ATRA Nasdaq
- PEPG Nasdaq
- Market Cap
- ATRA 65.1M
- PEPG 64.2M
- IPO Year
- ATRA 2014
- PEPG 2022
- Fundamental
- Price
- ATRA $9.44
- PEPG $1.23
- Analyst Decision
- ATRA Buy
- PEPG Buy
- Analyst Count
- ATRA 6
- PEPG 3
- Target Price
- ATRA $25.70
- PEPG $14.67
- AVG Volume (30 Days)
- ATRA 436.6K
- PEPG 277.5K
- Earning Date
- ATRA 03-27-2025
- PEPG 03-05-2025
- Dividend Yield
- ATRA N/A
- PEPG N/A
- EPS Growth
- ATRA N/A
- PEPG N/A
- EPS
- ATRA N/A
- PEPG N/A
- Revenue
- ATRA $100,439,000.00
- PEPG N/A
- Revenue This Year
- ATRA $1,339.87
- PEPG N/A
- Revenue Next Year
- ATRA N/A
- PEPG N/A
- P/E Ratio
- ATRA N/A
- PEPG N/A
- Revenue Growth
- ATRA 2111.34
- PEPG N/A
- 52 Week Low
- ATRA $5.40
- PEPG $1.20
- 52 Week High
- ATRA $28.75
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- ATRA 44.94
- PEPG 15.20
- Support Level
- ATRA $8.02
- PEPG $1.77
- Resistance Level
- ATRA $9.10
- PEPG $2.03
- Average True Range (ATR)
- ATRA 1.12
- PEPG 0.24
- MACD
- ATRA -0.02
- PEPG -0.03
- Stochastic Oscillator
- ATRA 45.13
- PEPG 3.32
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.